Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy.’ The study aims to assess the safety and efficacy of upadacitinib, an oral medication, in treating moderate to severe hidradenitis suppurativa (HS) in patients unresponsive to anti-TNF therapy. This research is significant as it explores a potential new treatment avenue for HS, a painful inflammatory skin condition.
The intervention being tested is upadacitinib, an oral drug already approved for several inflammatory conditions. It is being evaluated for its effectiveness in treating HS, with the goal of reducing disease activity and monitoring adverse events.
The study design is interventional, randomized, and follows a parallel assignment model. It employs quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are unaware of the treatment allocation. The primary purpose is treatment-focused.
The study began on May 26, 2023, with an estimated primary completion date in 2025 and the last update submitted on August 21, 2025. These dates are crucial for tracking the study’s progress and anticipated results.
This update could positively impact AbbVie’s stock performance by potentially expanding its market share in dermatological treatments. Investor sentiment may be influenced by the prospect of upadacitinib becoming a new standard for HS treatment, especially if competitors lack similar offerings.
The study is ongoing, and further details are available on the ClinicalTrials portal.